Pauza Charles David
Transaction: 07/09/2026
BUY
Change
+97,000
Price
$0.68
Filing
07/16/2026
Type
BUY
Traws Pharma, Inc.
TRAW • Biotechnology
$0.38
▲ +0.00 (+0.58%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$4.08M
Growth
-50.6%
Cash Flow
0/5
Trend
Negative
Evidence
Reasonable earnings multiple · 1.01Manageable debt level · 0Weak liquidity · 0.72Negative growth trend
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 15, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:18 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.38
Change0.58%
Shares Out10.64M
Market Cap$4.08M
Enterprise Value$942.36K
52W Range0.43 - 3.27
Beta1.56
P/E-0.17
P/S1.46
P/B-0.77
P/FCF-0.27
EV/Sales0.34
Price$0.38
Change0.58%
Shares Out10.64M
Market Cap$4.08M
Enterprise Value$942.36K
52W Range0.43 - 3.27
Beta1.56
P/E-0.17
P/S1.46
P/B-0.77
P/FCF-0.27
EV/Sales0.34
EV/EBITDA-0.04
EV/FCF-0.06
Earnings Yield-587.43%
FCF Yield-376.73%
Dividend Yield0.00%
Gross Margin100.00%
Oper. Margin-6.41%
Profit Margin3.29%
Debt/Eq0.00
Current Ratio0.72
Quick Ratio0.72
Revenue 5Y-50.61%
Target$1.00
Target Upside163.92%
Target Median$1.00
Target Range1.00 - 1.00
Volume74.96K
Avg Volume2.35M
EPS Surprise0.39
Investment DNA
How strong this company looks for long-term investors
41
out of 100
Business Quality
Margins, moat, returns
41/100
Financial Strength
Debt, cash, stability
25/100
Growth Potential
Revenue and expansion
23/100
Price Attractiveness
Cheap or expensive today
85/100
Why this score▼
Reasonable earnings multiple · 1.01Manageable debt level · 0Weak liquidity · 0.72Negative growth trend
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 2 analyst votes · 2026-10-20
50/100
Neutral
Bullish
0
Hold
2
Bearish
0
Price Target
2026-08-16
Low
$1.00
Mean
$1.00
Median
$1.00
High
$1.00
Insider Transactions
Recent executive and insider activity
Savchuk Nikolay
Transaction: 07/09/2026
BUY
Change
+93,000
Price
$0.68
Filing
07/15/2026
Type
BUY
CAUTREELS WERNER
Transaction: 07/09/2026
BUY
Change
+14,150
Price
$0.68
Filing
07/15/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Pauza Charles David | BUY | +97,000 | $0.68 | 07/09/2026 | 07/16/2026 |
| Savchuk Nikolay | BUY | +93,000 | $0.68 | 07/09/2026 | 07/15/2026 |
| CAUTREELS WERNER | BUY | +14,150 | $0.68 | 07/09/2026 | 07/15/2026 |
| Leaman John Harold | BUY | +14,150 | $0.68 | 07/09/2026 | 07/14/2026 |
| Clarke Trafford | BUY | +14,150 | $0.68 | 07/09/2026 | 07/14/2026 |
| Shoemaker Mary Teresa | BUY | +14,150 | $0.68 | 07/09/2026 | 07/14/2026 |
| Parker Charles Nolan | BUY | +90,000 | $0.68 | 07/09/2026 | 07/14/2026 |
| Redfield Robert | BUY | +84,000 | $0.68 | 07/09/2026 | 07/14/2026 |
| Dukes Iain D. | BUY | +274,000 | $0.68 | 07/09/2026 | 07/14/2026 |
| STOVER JACK E | BUY | +14,150 | $0.68 | 07/09/2026 | 07/14/2026 |
| ORBIMED ADVISORS LLC | BUY | +597,729 | $1.67 | 04/16/2026 | 04/28/2026 |
| ORBIMED ADVISORS LLC | BUY | +597,729 | $1.67 | 04/16/2026 | 04/28/2026 |
| ORBIMED ADVISORS LLC | BUY | +597,729 | $1.67 | 04/16/2026 | 04/28/2026 |
| ORBIMED ADVISORS LLC | BUY | +1,793,187 | $1.67 | 04/16/2026 | 04/28/2026 |
| Parker Charles Nolan | BUY | +104,544 | $1.60 | 03/08/2026 | 04/08/2026 |
| Parker Charles Nolan | BUY | +15,393 | Not reported | 12/12/2025 | 04/08/2026 |
| Parker Charles Nolan | BUY | +61,571 | $2.33 | 12/12/2025 | 04/08/2026 |
| Parker Charles Nolan | BUY | +32,406 | $3.01 | 10/12/2025 | 04/08/2026 |
| Parker Charles Nolan | OTHER | 0 | Not reported | 07/03/2025 | 04/08/2026 |
| Shoemaker Mary Teresa | BUY | +33,435 | $1.60 | 03/08/2026 | 03/10/2026 |